Quest Diagnostics Inc vs Expedia Group Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Expedia Group Inc trades at $326.02 (market cap $38.53B). The key difference: Expedia Group Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | EXPE | |
|---|---|---|
Market Cap | $26.21B | $38.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $321.07 |
52-Week Low | $173.49 | $188.51 |
Enterprise Value | $31.97B | $37.09B |
Dividend Yield | 1.45% | 0.6% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Expedia Group (EXPE) trades at $328.08, up 4.48% on the day, reflecting strong momentum after Q2 2026 earnings beat. The stock shows a bullish technical trend with moving averages aligned positively, while fundamentals highlight robust revenue growth, expanding margins, and consistent earnings outperformance. Recent news emphasizes AI integration and B2B growth driving upward guidance revisions.
Outlook remains favorable with raised full-year revenue guidance and solid cash flow generation, though elevated valuation multiples and overbought RSI levels near-term pose risks. Analyst consensus leans neutral with a $322.95 price target slightly below current levels, suggesting cautious optimism amid execution and competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →